BioMarin/$BMRN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BioMarin
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
- Ticker
- $BMRN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,221
- Headquarters
- San Rafael, United States
- Website
- www.biomarin.com
BioMarin Metrics
BasicAdvanced
$11B
-
-$0.10
0.23
-
Price and volume
Market cap
$11B
Beta
0.23
52-week high
$70.98
52-week low
$49.26
Average daily volume
2.5M
Financial strength
Current ratio
2.443
Quick ratio
1.129
Long term debt to equity
0.562
Total debt to equity
0.667
Interest coverage (TTM)
4.24%
Profitability
EBITDA (TTM)
836.396
Gross margin (TTM)
53.21%
Net profit margin (TTM)
-0.52%
Operating margin (TTM)
15.84%
Effective tax rate (TTM)
143.78%
Revenue per employee (TTM)
$1,130,000
Management effectiveness
Return on assets (TTM)
3.77%
Return on equity (TTM)
-0.31%
Valuation
Price to revenue (TTM)
2.938
Price to book
1.72
Price to tangible book (TTM)
13.27
Price to free cash flow (TTM)
19.121
Free cash flow yield (TTM)
5.23%
Free cash flow per share (TTM)
2.911
Growth
Revenue change (TTM)
18.14%
Earnings per share change (TTM)
-103.70%
3-year revenue growth (CAGR)
16.52%
10-year revenue growth (CAGR)
13.34%
3-year earnings per share growth (CAGR)
-49.52%
10-year earnings per share growth (CAGR)
-28.63%
What the Analysts think about BioMarin
Analyst ratings (Buy, Hold, Sell) for BioMarin stock.
Analyst projections of the future price of BioMarin stock.
Bulls say / Bears say
BioMarin’s commercial base is growing: third-quarter revenue rose 32% to $1.025 billion, with metabolic-condition revenue up 44%. The newly added GALAFOLD and POMBILITI + OPFOLDA brands also showed patient growth, broadening the sources of sales. (BioMarin)
VOXZOGO could reach a larger market if approved for hypochondroplasia: its Phase 3 trial showed statistically significant improvements in growth measures, and the FDA decision is due by 30 May 2027. It could become the first targeted treatment for this condition. (BioMarin)
A settlement with Ascendis turns a patent dispute over Yuviwel into a royalty stream for BioMarin. It is due 20% of US net sales and 18% in the EU, Brazil and South Korea through May 2030. (BioMarin)
BioMarin cut its 2026 revenue outlook after one international customer deferred about $70 million of orders, and it cited worsening customer liquidity disruption in the Middle East. This highlights the risk that lumpy order timing can make reported growth less predictable. (BioMarin)
Acquisition and pipeline investment costs are weighing on earnings: BioMarin reported a $123 million third-quarter GAAP loss, citing acquisition-related costs, higher interest expense and acquired research charges. It cut its 2026 adjusted EPS outlook to $2.80–$3.10 from $4.90–$5.10. (BioMarin)
BioMarin stopped developing BMN 401 after its Phase 3 study failed to show clinical benefit on a key endpoint, despite improving a biomarker. Losing the programme removes a potential growth asset and underlines the risk that early biological signals may not translate into patient benefit. (BioPharma Dive, Fierce Biotech)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
BioMarin Financial Performance
Revenues and expenses
BioMarin Earnings Performance
Company profitability
Upcoming events
No upcoming events
BioMarin News
AllArticlesVideos
Funds containing BioMarin
AllUSDEURGBP
Fund name | Fund size | $BMRN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.72% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.72% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.32% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.32% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.